Physicians treating patients affected by nonmuscle-invasive bladder cancer (NMIBC) have
been in shock during the last six years since manufacturing restrictions on the production of …

Purpose: This systematic review assessed compliance to guidelines for the management of
nonmuscle-invasive bladder carcinoma (NMIBC). Methods: The PUBMED, Web of Science …

Background NKTR-255 is a novel polyethylene glycol-conjugate of recombinant human
interleukin-15 (rhIL-15), which was designed to retain all known receptor binding …

Abstract Purpose of Review Non-muscle-invasive bladder cancer (NMIBC) is a
heterogenous malignancy with high recurrence and progression rates, which necessitate …

Simple Summary Non-muscle-invasive bladder cancer is associated with its high rates of
progression and recurrence, the proper diagnosis and management can save lives. Bladder …

Background To explore possible solutions to overcome chronic Bacillus Calmette–Guérin
(BCG) shortage affecting seriously the management of non-muscle invasive bladder cancer …

Bladder cancer is the 10th most frequently diagnosed cancer worldwide with 5-year survival
rate around 70%. The current first-line treatment for non-muscle invasive bladder cancer is …

The current landscape of salvage therapies for patients with... : Current Opinion in Urology The
current landscape of salvage therapies for patients with bacillus Calmette-Guérin unresponsive …

Introduction Repeat BCG induction remains an option for select non-muscle invasive
bladder cancer (NMIBC) patients who fail initial therapy. Alternative salvage intravesical …

Objective To compare the efficacy and safety of intra-arterial chemotherapy (IAC) combined
with intravesical chemotherapy (IVC) against intravesical BCG immunotherapy in high-risk …